Guangdong Xijie Pharmaceutical

Guangdong Xijie Pharmaceutical is an innovative specialty pharmaceutical company focused on the development of improved new drugs (Class 2) and high-end generics. Founded in 2019 and headquartered in the Zhuhai International Health Port, the company specializes in overcoming the challenges of poorly soluble drugs through its proprietary formulation platforms. These include a Nanocrystal Drug Technology Platform and a Nano-Solid Dispersion Technology Platform, which enhance the bioavailability, safety, and patient compliance of small molecule therapeutics. Xijie Pharmaceutical's pipeline primarily targets oncology, urological disorders, and cardiovascular diseases. Its lead candidate, a generic vardenafil hydrochloride tablet for erectile dysfunction and pulmonary arterial hypertension, has been submitted for marketing approval in China. Additionally, the company operates a Macau-based subsidiary, JANEVIS Biotechnology, which applies nanotechnology to traditional Chinese medicine and health supplements.